| 1 |
Raina R, Vijayvargiya N, Khooblall A, Melachuri M, Deshpande S, Sharma D, Mathur K, Arora M, Sethi SK, Sandhu S. Pediatric Atypical Hemolytic Uremic Syndrome Advances. Cells 2021;10:3580. [PMID: 34944087 DOI: 10.3390/cells10123580] [Reference Citation Analysis]
|
| 2 |
Ehren R, Habbig S. Real-world data of six patients with atypical hemolytic uremic syndrome switched to ravulizumab. Pediatr Nephrol 2021;36:3281-2. [PMID: 34274988 DOI: 10.1007/s00467-021-05203-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 3 |
Devarajan P, Chertow GM, Susztak K, Levin A, Agarwal R, Stenvinkel P, Chapman AB, Warady BA. Emerging Role of Clinical Genetics in CKD. Kidney Medicine 2022. [DOI: 10.1016/j.xkme.2022.100435] [Reference Citation Analysis]
|
| 4 |
Sangeetha G, Jayaraj J, Ganesan S, Puttagunta S. Atypical haemolytic uraemic syndrome: a case of rare genetic mutation. BMJ Case Rep 2021;14:e244190. [PMID: 34330731 DOI: 10.1136/bcr-2021-244190] [Reference Citation Analysis]
|
| 5 |
Levy AR, Chen P, Johnston K, Wang Y, Popoff E, Tomazos I. Quantifying the economic effects of ravulizumab versus eculizumab treatment in patients with atypical hemolytic uremic syndrome. J Med Econ 2022;:1-16. [PMID: 35020547 DOI: 10.1080/13696998.2022.2027706] [Reference Citation Analysis]
|
| 6 |
Syed YY. Ravulizumab: A Review in Atypical Haemolytic Uraemic Syndrome. Drugs 2021;81:587-94. [PMID: 33738756 DOI: 10.1007/s40265-021-01481-6] [Reference Citation Analysis]
|
| 7 |
Zununi Vahed S, Rahbar Saadat Y, Ardalan M. Thrombotic microangiopathy during pregnancy. Microvasc Res 2021;138:104226. [PMID: 34252400 DOI: 10.1016/j.mvr.2021.104226] [Reference Citation Analysis]
|
| 8 |
Brodsky RA. Eculizumab and aHUS: to stop or not. Blood 2021;137:2419-20. [PMID: 33956069 DOI: 10.1182/blood.2020010234] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 9 |
Dixon BP, Sabus A. Ravulizumab 100 mg/mL formulation reduces infusion time and frequency, improving the patient and caregiver experience in the treatment of atypical haemolytic uraemic syndrome. J Clin Pharm Ther 2022. [PMID: 35304755 DOI: 10.1111/jcpt.13642] [Reference Citation Analysis]
|
| 10 |
Palma LMP, Vaisbich-Guimarães MH, Sridharan M, Tran CL, Sethi S. Thrombotic microangiopathy in children. Pediatr Nephrol 2022. [PMID: 35041041 DOI: 10.1007/s00467-021-05370-8] [Reference Citation Analysis]
|
| 11 |
Yoo JJ, Chonat S. Evaluating ravulizumab for the treatment of children and adolescents with paroxysmal nocturnal hemoglobinuria. Expert Rev Hematol 2022. [PMID: 35502699 DOI: 10.1080/17474086.2022.2073215] [Reference Citation Analysis]
|
